Please assess the completion status of the following clinical trial:

Trial Title: A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Understand and voluntarily sign an informed consent form.~* Age greater than 18 years at the time of signing the informed consent form.~* Able to adhere to the study visit schedule and other protocol requirements.~* Diagnosed with active multiple myeloma and be considered to have disease progression after at least 2 cycles of anti-myeloma treatment or have relapsed with progressive disease after treatment.~* Measurable myeloma paraprotein levels in serum (≥ 0.5g/dL) or urine (≥ 0.2 g excreted in a 24-hour collection sample).~* Eastern Cooperative Group (ECOG) Performance Status of 0-2. Performance status of 3 and 4 will be allowed if related to bony disease.~* Bilirubin \< 2 x upper limits of normal (ULN).~* Liver enzymes (ALT or AST) \< 3 x ULN.~* Must have adequate bone marrow function: \* Absolute neutrophil count \> 1,000 cells/mm3 (1.0 x 109/L) \* Platelets ≥ 100,000 cells/mm3 (100 x 109/L) \* Hemoglobin ≥ 8 g/dL~* Must have adequate renal function: creatinine ≤ 2.5 mg/dL.~* Must have 2-d echocardiogram indicating LVEF ≥ 50% within 42 days prior to first dose of study drug.~* Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug. WCBP must agree to have pregnancy tests every 4 weeks while on study drug.~Exclusion Criteria:~* Severe infection requiring intravenous antibiotic treatment.~* Life expectancy of less than 3 months.~* Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in-situ cervical cancer, or other cancer from which the subject has been disease-free for at least 5 years.~* Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia.~* Subjects who have received \> 500mg/m2 of doxorubicin alone, or Doxil® alone, or doxorubicin plus Doxil®.~* Prior treatment with CC-5013.~* Prior development of ≥ grade 2 (NCI CTC) allergic reaction/hypersensitivity while taking thalidomide.~* Prior development of a ≥ grade 3 (NCI CTC) rash or any desquamation while taking thalidomide.~* History of cardiac disease, with New York Heart Association Class II or greater.~* Uncontrolled medical problems such as diabetes mellitus, coronary artery disease, hypertension, unstable angina, arrhythmias), pulmonary, hepatic and renal diseases unless renal insufficiency is felt to be secondary to multiple myeloma.~* Any investigational agent or systemic anti-myeloma therapy within 28 days of the first dose of treatment.~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.~* Pregnant or lactating females.~* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).